Eight-year follow-up study of brain atrophy in patients with MS.
about
Association of retinal and macular damage with brain atrophy in multiple sclerosisNeurodegeneration in multiple sclerosis: novel treatment strategiesContinuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateOptimizing treatment success in multiple sclerosisThe role of neurotrophins in multiple sclerosis-pathological and clinical implicationsBiomarkers in Multiple Sclerosis: An Up-to-Date OverviewComparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosisThe mechanism of action of interferon-β in relapsing multiple sclerosisRevisiting brain atrophy and its relationship to disability in multiple sclerosisSyMRI of the Brain: Rapid Quantification of Relaxation Rates and Proton Density, With Synthetic MRI, Automatic Brain Segmentation, and Myelin Measurement.Clinical use of brain volumetry.Bringing CLARITY to gray matter atrophy.Clinical relevance of brain volume measures in multiple sclerosis.Sub-millimeter imaging of brain-free water for rapid volume assessment in atrophic brains.The role of the cerebellum in multiple sclerosis.Statin treatment in multiple sclerosis: a systematic review and meta-analysis.Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect modelsBiomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.Imaging of multiple sclerosis: role in neurotherapeutics.Magnetic resonance imaging advances in multiple sclerosis.Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis.Magnetic resonance imaging measures of brain atrophy in multiple sclerosis.Does hydration status affect MRI measures of brain volume or water content?Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Measuring brain atrophy in multiple sclerosis.Imaging as an Outcome Measure in Multiple Sclerosis.Brain MRI atrophy quantification in MS: From methods to clinical application.[Multiple sclerosis].Measurement of whole-brain atrophy in multiple sclerosis.Central nervous system atrophy and clinical status in multiple sclerosis.Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosisPredicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.Neuroimaging in multiple sclerosis: neurotherapeutic implications.Advanced MRI in multiple sclerosis: current status and future challengesTargeting progressive neuroaxonal injury: lessons from multiple sclerosis.
P2860
Q21135504-7815657F-B4ED-43F0-B71F-EB7D8568D703Q22241472-019902B9-B8F3-46AE-88AB-D54622B835C5Q24602567-A5454994-757C-4D97-8DB1-CC1928FDAA24Q26771968-5FD53A5A-18A9-4E9F-BF80-38A3CDE2F750Q26849274-256381EE-0741-4321-AC41-03471E7C9D6EQ27496017-8A5634F9-AFB2-46E5-96CC-9C352C51280AQ28081636-4A00B381-B6CA-4670-BF2B-86E89129BC24Q28239752-50C89B37-13C8-4EE9-9A69-96754AB08C7AQ28729953-828E9F67-8693-4719-A2BA-F454C9D883DAQ30491047-7ABD2ABB-B393-4B09-8829-CB6C54AA28B2Q30582479-28456290-CDB1-4F70-9C21-78CEAED956B5Q30651109-71D38923-106A-422E-83FA-3F4FB443A553Q30738659-FDDE47EA-A35D-4B31-BA76-58C28AD81626Q30832217-2F013FB6-9773-4816-B694-64ADA773531CQ30884001-C4D61756-0265-480A-AA7C-7D84E64220E3Q30913423-24FBA6F3-D0C5-4A46-87ED-ADDCC3F8C358Q30982037-B15083EA-92B5-4F4B-A857-0EC59DAD8DD9Q30983016-1A7E78FA-D0E2-41D3-9129-AF28B7A01CDFQ30985817-9CB0F8A3-8487-40CD-9406-D042B09457E1Q30989935-8B9F9E30-6CAE-478B-899F-F4A4EB3E289AQ31027940-6210B80E-2C60-456D-B7AD-5463AC9C2515Q31027953-02ADBA76-33A2-4D69-8C57-1A38B5B6B281Q31036129-5FE92950-E239-43D9-B750-83EA72015A38Q31041141-DB29664F-C26A-4E6D-BDB2-21E93142DCC3Q31070072-D40344E4-34D1-4F19-8A49-3C735C83ADAEQ31108858-585CF07F-68E6-4CF4-97BB-1F5058018E4FQ31134617-F78A49D4-229A-4D9A-80A9-579D90C7C952Q31149648-64AB826A-9B91-4C12-A52D-A16C71E5487FQ31156621-488F256E-FA85-4E0F-9B92-ACA7C69F13E8Q33204391-6891EF57-1529-43D8-83AA-96F549A27120Q33204392-1B5A29FB-613C-451B-8AAF-B8B0A92E31C0Q33204393-5A7CE266-5AD6-42F8-A4E0-DE1E91C57411Q33427934-797EB04C-B3A8-461C-8225-A9E7AEC48FDFQ33500910-C6972D6C-2E72-4C38-8EF5-16F9C682837FQ33692568-EE099786-0059-4873-9B92-7C72B580CBFFQ33693097-15E68AFB-EA8B-4FB5-ABDC-68B398DB92DAQ33791632-FF3F0F4F-30FF-4844-808D-A3CC7D1C59ECQ33806032-A895109B-5A4E-44D3-AEF8-BF29DCDBD385Q33856615-786E212D-AAB8-43DE-B3B2-EE62B9F6230DQ34003724-54C43B0A-EE06-4CF0-913F-C4BE07D5A06A
P2860
Eight-year follow-up study of brain atrophy in patients with MS.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Eight-year follow-up study of brain atrophy in patients with MS.
@en
Eight-year follow-up study of brain atrophy in patients with MS.
@nl
type
label
Eight-year follow-up study of brain atrophy in patients with MS.
@en
Eight-year follow-up study of brain atrophy in patients with MS.
@nl
prefLabel
Eight-year follow-up study of brain atrophy in patients with MS.
@en
Eight-year follow-up study of brain atrophy in patients with MS.
@nl
P2093
P1433
P1476
Eight-year follow-up study of brain atrophy in patients with MS.
@en
P2093
Dougherty DS
Simonian NA
P304
P356
10.1212/01.WNL.0000036271.49066.06
P407
P577
2002-11-01T00:00:00Z